---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-005435"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-01-14T23:59:59+00:00"
generated_at: "2026-05-28T02:05:26.447313+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Crinetics outlines 2025 milestones: paltusotine PDUFA Sept 25, atumelnant Ph3 start H1 2025

## Summary
- Paltusotine NDA under FDA review; PDUFA target action date set for September 25, 2025.
- Atumelnant Phase 3 initiation for adult CAH patients expected in H1 2025; pediatric CAH and Cushing's disease later-stage trials planned in 2025.
- Four development candidates advancing toward IND-enabling studies for NETs, hyperparathyroidism, Graves' disease, thyroid eye disease, and ADPKD.
- CEO Scott Struthers presenting at 43rd J.P. Morgan Healthcare Conference on January 14, 2025.

## SEC filing metadata
- accession: 0000950170-25-005435
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-01-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017025005435/0000950170-25-005435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017025005435/crnx-20250114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-005435
- JSON: https://secwatch.observer/filing/0000950170-25-005435.json
- Plain text: https://secwatch.observer/filing/0000950170-25-005435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.